• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Mucositis - Pipeline Review, H2 2012 Product Image

Mucositis - Pipeline Review, H2 2012

  • Published: September 2012
  • 46 pages
  • Global Markets Direct

Mucositis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Mucositis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucositis. Mucositis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mucositis.
- A review of the Mucositis products under development by companies and universities/research institutes based on information derived from company and READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Mucositis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Mucositis 7
Mucositis Therapeutics under Development by Companies 9
Mucositis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Mucositis Therapeutics – Products under Development by Companies 15
Mucositis Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Mucositis Therapeutics Development 17
Daewoong Pharmaceutical Co., Ltd. 17
NPS Pharmaceuticals, Inc. 18
Mundipharma International Limited 19
7TM Pharma A/S 20
Avaxia Biologics, Inc. 21
Canopus BioPharma Incorporated 22
Mucositis – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
teduglutide - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
nepidermin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
oltipraz - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
buprenorphine hydrochloride - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CR-3294 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
curcumin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Mucositis Therapeutics – Drug Profile Updates 35
Mucositis Therapeutics – Discontinued Products 38
Mucositis Therapeutics - Dormant Products 39
Mucositis – Product Development Milestones 40
Featured News & Press Releases 40
Aug 02, 2011: Access Pharmaceuticals MuGard Added To Humana's Pharmacy Drug Benefit Network 40
Jul 13, 2011: BioAlliance Announces Validation Of Orphan Drug Designation Application For Clonidine Lauriad 40
Jun 24, 2011: BioAlliance Pharma Submits Application For Orphan Medicinal Product Designation For Clonidine Lauriad In Europe And US 40
Jun 04, 2011: SciClone's SCV-07 Demonstrates Antitumor Activity In Various Cancer Xenograft Studies In Mice 41
May 18, 2011: SciClone To Present New Preclinical Data On SCV-07 At 2011 ASCO Annual Meeting 42
Feb 09, 2011: Access Pharmaceuticals Receives Early MuGard Prescriber Anecdotal Feedback Validating Larger Target Market Potential 42
Mar 31, 2010: PolyMedix Completes Phase IB Clinical Study With Antibiotic PMX-30063 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Mucositis, H2 2012 7
Products under Development for Mucositis – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Daewoong Pharmaceutical Co., Ltd., H2 2012 17
NPS Pharmaceuticals, Inc., H2 2012 18
Mundipharma International Limited, H2 2012 19
7TM Pharma A/S, H2 2012 20
Avaxia Biologics, Inc., H2 2012 21
Canopus BioPharma Incorporated, H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Mucositis Therapeutics – Drug Profile Updates 35
Mucositis Therapeutics – Discontinued Products 38
Mucositis Therapeutics – Dormant Products 39

List of Figures
Number of Products under Development for Mucositis, H2 2012 7
Products under Development for Mucositis – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos